Takara Bio Inc.

Equities

4974

JP3460200003

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-23 am EDT			5-day change	1st Jan Change
1,036 ^JPY	-4.78%		-4.78%	-17.25%

May. 10	Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024	CI
Mar. 18	Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index	CI

Takara Bio Inc. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2020

February 10, 2021 at 03:00 am EST

Takara Bio Inc. announced consolidated earnings results for the nine months ended December 31, 2020. For the period, the company announced net sale of JPY 29,549 million against JPY 24,558 million a year ago. Operating profit was JPY 8,791 million against JPY 3,879 million a year ago. Net income attributable to owners of parent was JPY 5,726 million against JPY 2,708 million a year ago. Fully diluted net income per share was JPY 47.56 against JPY 22.49 a year ago.

Latest news about Takara Bio Inc.

Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024	May. 10	CI
Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index	Mar. 17	CI
Takara Bio's Attributable Income Falls 98.9% in Fiscal Nine Months	Feb. 15	MT
Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Nov. 09	CI
Jefferies Adjusts Takara Bio’s Price Target to 1,900 Yen From 2,000 Yen, Keeps at Hold	23-07-25	MT
Takara Bio Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-11	CI
Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023	23-02-09	CI
Takara Bio Inc. Revised Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-02-09	CI
Takara Bio Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-11-10	CI
Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023	22-11-10	CI
Takara Bio Posts Extraordinary Gains and Losses over Subsidy Grants	22-01-24	MT
Takara Bio Inc. Revises Year End Dividend Guidance for the Full Year Ending March 31, 2022	21-11-09	CI
Takara Bio Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2022	21-11-09	CI
Takara Bio : Raises Earnings Forecast for Fiscal H1	21-10-22	MT
Takara Bio Eligible to List on Tokyo Bourse's Prime Market	21-09-22	MT
Takara Bio Inc. Provides Dividend Guidance for the Year Ending March 31, 2022	21-08-06	CI
Takara Bio Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2021	21-08-06	CI
Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021 and Full Year Ending March 31, 2022	21-08-06	CI
Takara Bio Inc. Reports Unaudited Consolidated Earnings Results for the Year Ended March 31, 2021	21-05-13	CI
Takara Bio Inc. Announces Dividend for the Year Ended March 31, 2021	21-05-13	CI
Takara Bio Inc. Provides Dividend Guidance for the Year Ending March 31, 2022	21-05-13	CI
Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021; Provides Earnings Guidance for the Year Ending March 31, 2022	21-05-13	CI
Takara Bio : Attribute Net Income Surges 111% in April-December 2020	21-02-11	MT
Takara Bio Inc. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2020	21-02-10	CI
Takara Bio Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2021	21-02-10	CI

Chart Takara Bio Inc.

Duration

Period

More charts

Company Profile

TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Takara Bio Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,036 JPY

Average target price

1,567 JPY

Spread / Average Target

+51.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TAKARA BIO INC.	-17.25%	837M
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research